CN116322642B - 多糖衍生物、多糖衍生物-药物缀合物、其制造方法 - Google Patents

多糖衍生物、多糖衍生物-药物缀合物、其制造方法 Download PDF

Info

Publication number
CN116322642B
CN116322642B CN202180056609.9A CN202180056609A CN116322642B CN 116322642 B CN116322642 B CN 116322642B CN 202180056609 A CN202180056609 A CN 202180056609A CN 116322642 B CN116322642 B CN 116322642B
Authority
CN
China
Prior art keywords
group
aba
polysaccharide
polysaccharide derivative
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180056609.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116322642A (zh
Inventor
伊藤大知
太田诚一
戚蟠
A·K·S·钱德尔
伊佐次三津子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
University of Tokyo NUC
Original Assignee
Mochida Pharmaceutical Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd, University of Tokyo NUC filed Critical Mochida Pharmaceutical Co Ltd
Priority to CN202411038895.8A priority Critical patent/CN118955760A/zh
Publication of CN116322642A publication Critical patent/CN116322642A/zh
Application granted granted Critical
Publication of CN116322642B publication Critical patent/CN116322642B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/14—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups
    • C08B11/15—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups with carbamoyl groups, i.e. -CO-NH2
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180056609.9A 2020-08-14 2021-08-10 多糖衍生物、多糖衍生物-药物缀合物、其制造方法 Active CN116322642B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411038895.8A CN118955760A (zh) 2020-08-14 2021-08-10 多糖衍生物、多糖衍生物-药物缀合物、其制造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-137010 2020-08-14
JP2020137010 2020-08-14
PCT/JP2021/029573 WO2022034889A1 (ja) 2020-08-14 2021-08-10 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411038895.8A Division CN118955760A (zh) 2020-08-14 2021-08-10 多糖衍生物、多糖衍生物-药物缀合物、其制造方法

Publications (2)

Publication Number Publication Date
CN116322642A CN116322642A (zh) 2023-06-23
CN116322642B true CN116322642B (zh) 2024-08-23

Family

ID=80247958

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180056609.9A Active CN116322642B (zh) 2020-08-14 2021-08-10 多糖衍生物、多糖衍生物-药物缀合物、其制造方法
CN202411038895.8A Pending CN118955760A (zh) 2020-08-14 2021-08-10 多糖衍生物、多糖衍生物-药物缀合物、其制造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411038895.8A Pending CN118955760A (zh) 2020-08-14 2021-08-10 多糖衍生物、多糖衍生物-药物缀合物、其制造方法

Country Status (8)

Country Link
US (1) US20230285577A1 (https=)
EP (1) EP4198060A4 (https=)
JP (2) JP7721539B2 (https=)
KR (1) KR20230061346A (https=)
CN (2) CN116322642B (https=)
AU (1) AU2021324708A1 (https=)
CA (1) CA3188951A1 (https=)
WO (1) WO2022034889A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023157150A1 (ja) * 2022-02-16 2023-08-24 持田製薬株式会社 多糖誘導体の用途
CN115991883B (zh) * 2022-12-26 2024-07-16 四川大学华西医院 一种用于消化道esd的水凝胶及其制备方法和用途
CN120267903B (zh) * 2025-06-06 2025-08-08 吉林大学 一种免疫调控水凝胶及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528780A (zh) * 2006-09-11 2009-09-09 费迪亚医药股份公司 通过“点击化学”交联而获得的透明质酸衍生物
CN101663038A (zh) * 2007-02-07 2010-03-03 烧津水产化学工业株式会社 含有组织滞留性脱乙酰壳多糖凝胶的抗肿瘤药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2855307B2 (ja) * 1992-02-05 1999-02-10 生化学工業株式会社 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法
JP4565691B2 (ja) 2000-02-28 2010-10-20 株式会社Phg ヘパリン結合性成長因子用徐放基材、およびヘパリン結合性成長因子徐放剤
RU2283848C1 (ru) * 2005-06-16 2006-09-20 Институт нефтехимии и катализа РАН Республика Башкортостан Способ получения конъюгатов альгиновой кислоты
IT1399351B1 (it) * 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
WO2014038641A1 (ja) * 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
EP3778653B1 (en) 2018-03-28 2025-07-09 Mochida Pharmaceutical Co., Ltd. Novel reactive alginic acid derivatives
JP7088075B2 (ja) 2019-02-22 2022-06-21 株式会社デンソー 電子制御装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528780A (zh) * 2006-09-11 2009-09-09 费迪亚医药股份公司 通过“点击化学”交联而获得的透明质酸衍生物
CN101663038A (zh) * 2007-02-07 2010-03-03 烧津水产化学工业株式会社 含有组织滞留性脱乙酰壳多糖凝胶的抗肿瘤药物组合物

Also Published As

Publication number Publication date
CA3188951A1 (en) 2022-02-17
EP4198060A4 (en) 2024-09-04
EP4198060A1 (en) 2023-06-21
JP7721539B2 (ja) 2025-08-12
US20230285577A1 (en) 2023-09-14
JPWO2022034889A1 (https=) 2022-02-17
AU2021324708A1 (en) 2023-03-09
JP2025156408A (ja) 2025-10-14
KR20230061346A (ko) 2023-05-08
WO2022034889A1 (ja) 2022-02-17
CN118955760A (zh) 2024-11-15
CN116322642A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
JP7830616B2 (ja) 多糖誘導体の用途
Zafar et al. Role of crosslinkers for synthesizing biocompatible, biodegradable and mechanically strong hydrogels with desired release profile
CN116322642B (zh) 多糖衍生物、多糖衍生物-药物缀合物、其制造方法
Tan et al. Controlled gelation and degradation rates of injectable hyaluronic acid‐based hydrogels through a double crosslinking strategy
KR101966555B1 (ko) 생체친화형 하이드로젤 및 제조방법
WO2009006780A1 (en) A method for the formation of a rapid-gelling biocompatible hydrogel and the preparation of a spraying agent
WO2008067655A1 (en) Biocompatible hydrogel-based scaffolds
CN102585303A (zh) 一种壳聚糖/聚赖氨酸原位凝胶及其制备方法
Vasiliu et al. Chitosan-based polyelectrolyte complex hydrogels for biomedical applications
Shi et al. Polymeric hydrogels for post-operative adhesion prevention: A review
US7879818B2 (en) Hyaluronic acid-based cross-linked nanoparticles
Youn et al. Tissue adhesives based on chitosan for biomedical applications
WO2016114355A1 (ja) 癒着防止用組成物
RU2713295C2 (ru) Способ сшивания полисахаридов при помощи фотоудаляемых защитных групп
WO2015174643A1 (ko) 표면 처리된 나노섬유를 포함하는 하이드로젤 및 이의 제조방법
JP2014528406A (ja) 治療薬を送達するための多層インプラント
CN106750416A (zh) 一种拥有自愈合和pH响应性能的可注射水凝胶及其制备方法和应用
Singh et al. Alginate-based hydrogels: synthesis, characterization, and biomedical applications
RU2708327C2 (ru) Производные сульфатированных полисахаридов, их способ получения, модификация и применение
CN117815431A (zh) 生物粘合剂及其制备、使用方法
Nagpal et al. Pharmaceutical applications of gellan gum
PT118075B (pt) Bioadesivos, métodos de preparação e suas aplicações
Al-Lami Preparation and release study of biodegradable L-lactide IPN’s insulin delivery
KR102869207B1 (ko) 주사 가능한 pH-반응성 하이드로겔
US9795717B2 (en) Enzymatically degradable compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant